|
1
|
Clark MA, Fisher C, Judson I and Thomas
JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zagars GK, Mullen JR and Pollack A:
Malignant fibrous histiocytoma: Outcome and prognostic factors
following conservation surgery and radiotherapy. Int J Radiat Oncol
Biol Phys. 34:983–994. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Le Cesne A, Blay JY, Judson I, Van
Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S,
Ray-Coquard I, Bonvalot S, et al: Phase II study of ET-743 in
advanced soft tissue sarcomas: a European Organitation for the
Research and Treatment of Cancer (EORTC) soft tissue and bone
sarcoma group trial. J Clin Oncol. 23:576–584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Demetri GD, Chawla SP, von Mehren M, Ritch
P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S,
et al: Efficacy and safety of trabectedin in patients with advanced
or metastatic liposarcoma or leiomyosarcoma after failure of prior
anthracyclines and ifosfamide: Results of a randomized phase II
study of two different schedules. J Clin Oncol. 27:4188–4196. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
DuBois S and Demetri G: Markers of
angiogenesis and clinical features in patients with sarcoma.
Cancer. 109:813–819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sleijfer S, van der Graaf WT and Blay JY:
Angiogenesis inhibition in non-GIST soft tissue sarcomas.
Oncologist. 13:1193–1200. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chao C, Al-Saleem T, Brooks JJ, Rogatko A,
Kraybill WG and Eisenberg B: Vascular endothelial growth factor and
soft tissue sarcomas: Tumor expression correlates with grade. Ann
Surg Oncol. 8:260–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sleijfer S, Ray-Coquard I, Papai Z, Le
Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De
Brauwer A, et al: Pazopanib, a multikinase angiogenesis inhibitor,
in patients with relapsed or refractory advanced soft tissue
sarcoma: A phase II study from the European organisation for
research and treatment of cancer-soft tissue and bone sarcoma group
(EORTC study 62043). J Clin Oncol. 27:3126–3132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppy Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kasper B, Sleijfer S, Litière S, Marreaud
S, Verweij J, Hodge RA, Bauer S, Kerst JM and van der Graaf WT:
Long-term responders and survivors on pazopanib for advanced soft
tissue sarcomas: Subanalysis of two European Organisation for
Research and Treatment of Cancer (EORTC) clinical trials 62043 and
62072. Ann Oncol. 25:719–724. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coens C, van der Graaf WT, Blay JY, Chawla
SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S, Prins
JB, et al: Health-related quality-of- life results from PALETTE: A
randomized, double-blind, phase 3 trial of pazopanib versus placebo
in patients with soft tissue sarcoma whose disease has progressed
during or after prior chemotherapy-a European Organization for
Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group
Global Network Study (EORTC 62072). Cancer. 121:2933–2941. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klempner SJ, Choueiri TK, Yee E, Doyle LA,
Schuppan D and Atkins MB: Severe pazopanib-induced hepatotoxicity:
Clinical and histologic course in two patients. J Clin Oncol.
30:e264–e286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
GlaxoSmithKline: Votrient (pazopanib)
tablets prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf
|
|
15
|
Santoni M, Conti A, De Giorgi U, Iacovelli
R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D and
Cascinu: Risk of gastrointestinal events with sorafenib, sunitinib
and pazopanib in patients with solid tumors: A systematic review
and meta-analysis of clinical trials. Int J Cancer. 135:763–773.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kapadia S, Hapani S, Choueiri TK and Wu S:
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in
cancer patients. Acta Oncol. 52:1202–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klapko O, Ghoulam E, Jakate S, Eswaram S
and Usha L: Anastrozole-induced autoimmune hepatitis: A rare
complication of breast cancer therapy. Anticancer research.
37:4173–4176. 2017.PubMed/NCBI
|
|
19
|
Vilgrain V, Lagadec M and Ronot M:
Pitfalls in Liver Imaging 2016. Radiology. 278:34–51. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Silva AC, Evans JM, McCullough AE, Jatoi
MA, Vargas HE and Hara AK: MR Imaging of hypervascular liver
masses: a review of current techniques. Radiographics. 29:385–402.
2009. View Article : Google Scholar : PubMed/NCBI
|
